Protalix BioTherapeutics
PLX
PLX
31 hedge funds and large institutions have $1.38M invested in Protalix BioTherapeutics in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
60% less call options, than puts
Call options by funds: $20K | Put options by funds: $50K
73% less capital invested
Capital invested by funds: $5.05M → $1.38M (-$3.67M)
Holders
31
Holding in Top 10
–
Calls
$20K
Puts
$50K
Top Buyers
| 1 | +$25.4K | |
| 2 | +$12.4K | |
| 3 | +$6K | |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$5K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$1.01K |
Top Sellers
| 1 | -$1.24M | |
| 2 | -$469K | |
| 3 | -$76.4K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$27.5K |
| 5 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$13.9K |